FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2499823072> ?p ?o ?g. }

• W2499823072 abstract "Abstract Clofarabine as a single agent has demonstrated activity in childhood acute leukemia. In the current phase I/II study, clofarabine was added to the widely used combination of etoposide and cyclophosphamide. The phase I component of the study is completed. Patients between 1 and 21 years old with refractory or relapsed acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML) were enrolled in phase I. A standard 3+3 design was followed to determine the safest dose when used in combination. All 3 drugs were administered via IV infusion daily for 5 consecutive days in induction and 4 consecutive days in consolidation. Patients received up to 2 induction cycles (depending on the response following cycle 1), followed by consolidation (up to a maximum of 8 cycles, including induction). The initial doses (cohort 1) were: clofarabine 20 mg/m2/day, etoposide 75 mg/m2/day and cyclophosphamide 340 mg/m2/day. Clofarabine was increased to 30 mg/m2/day in cohort 4 and 40 mg/m2/day in cohort 5 after cyclophosphamide and etoposide were escalated to their respective target dose levels (440 mg/m2/day and 100 mg/m2/day) in cohorts 2 and 3. Twenty-five patients (ALL: 20 patients; AML: 5 patients) were enrolled in the 5 cohorts, and response data based on investigator’s assessment are available on the first 22 patients (ALL: 18 patients; AML: 4 patients). The median number of prior induction regimens was 2, and 3 patients had a prior hematopoietic stem cell transplant (HSCT). Data show complete remission (CR) in 7 patients (ALL: 7 patients; AML: 0 patients) and complete remission without platelet recovery (CRp) in 6 patients (ALL: 2 patients; AML: 4 patients) for an overall response rate of 59% (ALL: 50%; AML: 100%). Four patients proceeded to HSCT after treatment. One patient in cohort 4 experienced a dose-limiting toxicity (DLT) that resolved (grade 3 elevation of lipase and abdominal pain). In addition, a second patient in cohort 4 experienced a lipase elevation that did not meet DLT criteria, leading to a cohort expansion to 10 total patients. One patient in cohort 5 (n=6) experienced a DLT of prolonged bone marrow aplasia leading to cohort expansion. Common toxicities observed in ≥20% of patients included febrile neutropenia, abdominal pain, diarrhea, nausea, vomiting, pyrexia, anorexia, hypokalemia, headache, anxiety and rash. As determined by the independent data monitoring committee, the recommended phase II doses of clofarabine, cyclophosphamide, etoposide 40mg/m2/day, 440 mg/m2/day, and 100 mg/m2/day, respectively. Encouraging preliminary efficacy results and an acceptable safety profile of the combination regimen warrants continuation of the phase II portion of the study, which is actively enrolling patients." @default.
• W2499823072 created "2016-08-23" @default.
• W2499823072 creator A5033141150 @default.
• W2499823072 creator A5033167405 @default.
• W2499823072 creator A5034653175 @default.
• W2499823072 creator A5037038601 @default.
• W2499823072 creator A5038841996 @default.
• W2499823072 creator A5038992066 @default.
• W2499823072 creator A5040026335 @default.
• W2499823072 creator A5042719910 @default.
• W2499823072 creator A5050897860 @default.
• W2499823072 creator A5062979200 @default.
• W2499823072 creator A5069354593 @default.
• W2499823072 creator A5075183737 @default.
• W2499823072 creator A5080485119 @default.
• W2499823072 date "2007-11-16" @default.
• W2499823072 modified "2023-09-30" @default.
• W2499823072 title "A Novel Therapy of Clofarabine in Combination with Etoposide and Cyclophosphamide Shows Activity in Pediatric Patients with Refractory or Relapsed Acute Leukemia." @default.
• W2499823072 doi "https://doi.org/10.1182/blood.v110.11.883.883" @default.
• W2499823072 hasPublicationYear "2007" @default.
• W2499823072 type Work @default.
• W2499823072 sameAs 2499823072 @default.
• W2499823072 citedByCount "1" @default.
• W2499823072 crossrefType "journal-article" @default.
• W2499823072 hasAuthorship W2499823072A5033141150 @default.
• W2499823072 hasAuthorship W2499823072A5033167405 @default.
• W2499823072 hasAuthorship W2499823072A5034653175 @default.
• W2499823072 hasAuthorship W2499823072A5037038601 @default.
• W2499823072 hasAuthorship W2499823072A5038841996 @default.
• W2499823072 hasAuthorship W2499823072A5038992066 @default.
• W2499823072 hasAuthorship W2499823072A5040026335 @default.
• W2499823072 hasAuthorship W2499823072A5042719910 @default.
• W2499823072 hasAuthorship W2499823072A5050897860 @default.
• W2499823072 hasAuthorship W2499823072A5062979200 @default.
• W2499823072 hasAuthorship W2499823072A5069354593 @default.
• W2499823072 hasAuthorship W2499823072A5075183737 @default.
• W2499823072 hasAuthorship W2499823072A5080485119 @default.
• W2499823072 hasConcept C121332964 @default.
• W2499823072 hasConcept C126322002 @default.
• W2499823072 hasConcept C141071460 @default.
• W2499823072 hasConcept C142424586 @default.
• W2499823072 hasConcept C2776611710 @default.
• W2499823072 hasConcept C2776694085 @default.
• W2499823072 hasConcept C2776755627 @default.
• W2499823072 hasConcept C2776863199 @default.
• W2499823072 hasConcept C2777198975 @default.
• W2499823072 hasConcept C2778041864 @default.
• W2499823072 hasConcept C2778119113 @default.
• W2499823072 hasConcept C2778461978 @default.
• W2499823072 hasConcept C71924100 @default.
• W2499823072 hasConcept C72563966 @default.
• W2499823072 hasConcept C87355193 @default.
• W2499823072 hasConcept C90924648 @default.
• W2499823072 hasConceptScore W2499823072C121332964 @default.
• W2499823072 hasConceptScore W2499823072C126322002 @default.
• W2499823072 hasConceptScore W2499823072C141071460 @default.
• W2499823072 hasConceptScore W2499823072C142424586 @default.
• W2499823072 hasConceptScore W2499823072C2776611710 @default.
• W2499823072 hasConceptScore W2499823072C2776694085 @default.
• W2499823072 hasConceptScore W2499823072C2776755627 @default.
• W2499823072 hasConceptScore W2499823072C2776863199 @default.
• W2499823072 hasConceptScore W2499823072C2777198975 @default.
• W2499823072 hasConceptScore W2499823072C2778041864 @default.
• W2499823072 hasConceptScore W2499823072C2778119113 @default.
• W2499823072 hasConceptScore W2499823072C2778461978 @default.
• W2499823072 hasConceptScore W2499823072C71924100 @default.
• W2499823072 hasConceptScore W2499823072C72563966 @default.
• W2499823072 hasConceptScore W2499823072C87355193 @default.
• W2499823072 hasConceptScore W2499823072C90924648 @default.
• W2499823072 hasLocation W24998230721 @default.
• W2499823072 hasOpenAccess W2499823072 @default.
• W2499823072 hasPrimaryLocation W24998230721 @default.
• W2499823072 hasRelatedWork W1964366647 @default.
• W2499823072 hasRelatedWork W2017212960 @default.
• W2499823072 hasRelatedWork W2052084086 @default.
• W2499823072 hasRelatedWork W2060421679 @default.
• W2499823072 hasRelatedWork W2360827738 @default.
• W2499823072 hasRelatedWork W2409923935 @default.
• W2499823072 hasRelatedWork W2412581327 @default.
• W2499823072 hasRelatedWork W3031323949 @default.
• W2499823072 hasRelatedWork W4252186577 @default.
• W2499823072 hasRelatedWork W213880076 @default.
• W2499823072 isParatext "false" @default.
• W2499823072 isRetracted "false" @default.
• W2499823072 magId "2499823072" @default.
• W2499823072 workType "article" @default.